Phase III trial for Romark's influenza drug underway

04/22/2013 | Pharmaceutical Business Review Online

Romark Laboratories has started patient enrollment for a late-stage study of its influenza drug NT-300, or nitazoxanide. The study will involve 1,400 patients with fever and other flu symptoms. The trial is expected to be finished during the 2013-2014 flu season.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC